

Index

A

- actb mRNA, 31
- Actin, 31
- Actin-based motility, 84
- Adenosine triphosphate (ATP), 42, 43, 58
- Adenylyl cyclase-associated protein-1 (CAP-1), 32
- Amylase secretion, 10
- Annular lipid binding, 22
- Aquaporin-1 (AQP1), 28, 30
- Aquaporin-6 (AQP6), 28
- Atomic force microscopy (AFM), 3, 5–8, 10–15, 18, 25–28, 74, 94, 95, 100
- ATP biosynthesis, 93
- ATP-dependent degradation, 43
- ATP-dependent protein folding, 50
- ATP-fueled actomyosin process, 80
- ATP synthesis
 - chemiosmotic hypothesis, 58
 - crystal structure of F_1 , 59
 - disease, 60
 - electron transport chain, 58
 - F_1F_0 holoenzyme nanomachine, 59
 - F_0 , 59
 - mitochondria, 58, 59
 - oxidative phosphorylation, 58
 - PMF, 58, 59
 - rotary action, 58
 - the α - and β -subunits, 59

B

- Bicarbonate transport metabolon, 99
- Bin/Amphiphysin/Rvs (BAR) domains, 22
- Biomolecular complexes, 91

- Bose–Einstein relation, 93
- Brain acid soluble protein 1 (BASP-1), 31

C

- Cadmium telluride quantum dots (CdTe QDs), 82
- Cartilage hair hypoplasia, 67
- CdTe-QD-based nanothermometry, 82
- Cell plasma membrane, 2, 3, 5
 - activities, 96
 - DPPC lipid, 97
 - free lipid incorporation, 98
 - intracellular organelles, 98
 - intra-vesicular fluid, 97
 - mass spectrometry, 97
 - molecular dynamic simulations, 98
 - NPyT molecular, 97
 - PBS, 97
 - physiological processes, 97
 - RBC, 96, 97
 - SNARE proteins, 99
 - transmission electron micrograph, 97
 - vesicles, 97
- Cell secretion, 5, 7
- Cellular nanomachines
 - ATP, 93
 - principle, 91
- Cellular rotary motors, 93
- Cellular supramolecular assemblies, 93
- Cellular supramolecular structures, 92
- Chaperonin
 - ATP-dependent protein folding, 50
 - disorders, 53
 - E. coli*, 51

- Chaperonin (*cont.*)
 GroEL, 51
 GroES, 51
 structure–function, 51, 52
- Charcot–Marie–Tooth syndrome, 53, 60
- Chemical-energy driven motors, 93
- Chemiosmotic hypothesis, 58
- Chiral-induced electron spin selectivity, 92
- Chirality, 92, 93
- Circular dichroism (CD), 82
- Cryo-crystallography, 64, 65
- 2,3-Cyclic nucleotide phosphodiesterase (CNPase), 18, 32
- Cystic fibrosis transmembrane conductance regulator (CFTR), 16
- Cytoskeletal proteins, 31
- D**
- D-amino acid-containing peptidoglycan polymer, 92
- D-amino acids, 92
- Defective ribosome biogenesis, 67
- Definitive therapy, 67
- Diamond–Blackfan anemia (DBA), 67
- Differential expansion microscopy (DiExM), 85
- Diffusion barrier, 74
- Dihydropyrimidinase-related protein-2 (DRP-2), 32
- Dihydropyrimidinase-related proteins, 18
- DNA, 63
- D-sugars, 92
- D-tryptophan, 92
- E**
- E. coli* GroEL–GroES protein-folding chaperone machinery, 51
- Electron, 74
- Electron microscopy (EM), 3, 6, 12, 15, 25, 33, 64, 72, 80
- Elongation factor G (EF-G), 66
- Endoplasmic reticulum (ER), 64
- Energy, 58
- Enthalpy, 93
- Escherichia coli*, 51
- Exocrine, 3
- F**
- Food and Drug Administration (FDA), 45
- Fractional vesicle content release
 α -amylase, 28–29
 AQP1, 28, 30
- cell secretion, 27
- G proteins, 30
- GTP-binding G-protein-mediated signaling pathway, 27
- ion channels, 30
- lipid bilayer, 28–29
- secretory vesicle swelling, 28–29
- ZGs, 27–29
- Fruit fly *Drosophila*, 83
- Fusion pores, 5, 9, 15, 18, 26
- G**
- Gel filtration chromatography, 16
- Golgi apparatus, 98
- Gp groE, 50
- G proteins, 30
- GroE, 50
- GroEL, 51
- GroES, 51
- Growth hormone (GH) secreting cells, 7, 8
- Guanosine triphosphate (GTP), 27–30
- Gyosin
 globular head region, 81
- G α 3 and v-ATPase immunoreactivity, 99
- H**
- Hereditary spastic paraplegia (HSP), 53
- Hsp60, 51
- I**
- Immunoisolation, 16
- Insulin-secreting mouse insulinoma, 99
- Intracellular organelles, 98
- Intra-vesicular amylase, 15
- Isobaric–isothermal ensemble, 101
- L**
- Lipid bilayers, 23
- Lipid-binding assays, 21
- Lipid-binding domains, 21
- M**
- Mass spectrometry, 17
- McKusick–Kaufman syndrome, 53
- Membrane-bound secretory vesicles, 99
- Membrane fusion reaction, 100
- Membrane proteins, 99
- Methyl beta-cyclodextrin (M- β CD), 99
- Microsomes, 64
- Mitochondria, 58–60

Molecular dynamics (MD), 100, 101
 mRNA, 63, 66
 Multimodal imaging approaches, 101
 Muscle atrogenes, 84
Mycobacterium tuberculosis, 60
 MyHC mRNA quantification, 83
 Myopathy, 84
 Myosin
 actin, 80
 actomyosin ATPase activity, 81
 ATP/ADP intermediate states, 81
 ATP-fueled actomyosin process, 80
 CdTe QDs, 82
 efficiency, 82
 EM, 80
 heads, 83
 ICU patients, 84
 molecular motor protein, 80
 molecule, 83
 motor protein and disease, 82–85
 non-invasive clinical examination, 84
 nucleotide-free “rigor” state, 81
 stroke model, 81

N
 Na⁺/K⁺ATPase activity, 31
 Nanoscale, 50
 NAP-22, 31, 32
N-ethylmaleimide-sensitive factor (NSF), 3, 95
 Neural network, 85
 Neurodegenerative diseases, 45
 Neuronal porosome-associated proteins, 17
 Neurotransmission, 31
 Neurotransmission-related disease, 33
 Non-annular lipids, 22
 Nuclear envelop, 72
 Nuclear genome mutations, 60
 Nuclear pore
 atomic force microscopy, 74
 bidirectional transport, 74
 cytoplasmic compartment, 74
 cytoplasmic filament, 75
 diffusion barrier, 74
 electron, 74
 EM, 72
 in vitro assays, 73
 nuclear basket nucleoporins, 75
 nuclear envelop, 72
 nuclear transport, 75
 nucleoporins, 72, 73
 ribonucleoprotein particles, 72
 Xenopus egg, 72
 yeast, 74
 Nuclear transport, 75

Nucleocytoplasmic transport defects, 75
 Nucleoporins, 72, 73, 75

O

Oxidative electron transport chain, 58
 Oxidative phosphorylation, 58
 Oxidative stress response, 84

P

Pancreatic acinar cells, 5, 6, 8
 Pauli exclusion principle, 92
 Phosphate buffered saline (PBS), 97
 Phosphatidylcholine (PC), 23
 Phosphatidylethanolamine (PE), 23, 99
 Phosphatidylserine (PS), 99
 Photon correlation spectroscopy (PCS), 11, 15
 Photon-driven synthetic molecular
 motor, 92–93
 Plasma membrane calcium ATPases
 (PMCA), 31
 Plasma membrane proteins, 99
 PMCA2, 31
 Polydeoxyadenosine (poly(A)), 93
 Porosome
 amylase secretion, 10
 annular lipid binding, 22
 apical plasma membrane, 9, 13
 BAR domains, 22
 cell secretion, 5, 7
 CFTP, 16
 CNPase, 18
 composition, 16
 cup-shaped lipoprotein structures, 7, 8, 10
 2D-BAC gels electrophoresis, 16
 3D contour map, 15
 disease, 31–33
 fractional vesicle content release (*see*
 Fractional vesicle content release)
 functional reconstitution
 lipid membrane, 23, 24
 live cells, 24
 GH cells, 8, 13
 health, 31–33
 immunoblot analysis, SNAP-25 immuno-
 pull-down, 18
 intra-vesicular amylase, 15
 intra-vesicular pressure, 4, 5
 isolation, 16
 lipid-binding domains, 21, 22
 lipids, 20, 21
 mass spectrometry, 17
 Na-K-ATPase, 22
 non-annular lipid binding, 22

- Porosome (*cont.*)
 NSF and dynamin, 18
 pancreatic acinar cells, 5–8
 pancreatic β -cells, 14
 PCS, 11
 plasma membrane, 5
 protein–protein interaction, 19
 proteins, 16–20
 secretory portals, 6, 7, 13
 secretory vesicles, 4, 5
 shape, 15
 size, 15
 SNAP-23, 12, 14
 SNARE proteins, 15
 sodium/potassium-transporting ATPase, 18
 spectrin, 22
 STRING 9.0, 19
 structure, 7, 9, 11
 SV, 11, 12
 t-/v-SNARE, 25, 26
 t-SNARE, 7, 12, 14, 16
 ZGM, 9
- Post-translational modifications
 (PTMs), 83, 84
- Presynaptic membrane (PSM), 12
- Proteasome, 44
 disease, 45
 interacting proteins, 44
 RP, 44
 19S RP, 44
 20S CP, 44
 26S, 43, 44
 treatments Targets, 45
 ubiquitin–proteasome-mediated protein
 degradation, 44
- Proton motive force (PMF), 58–60
- PS lipid-CHOL vs. PG lipid-CHOL, 99
- R**
- Radial distribution functions, 101
- Reactive oxygen species (ROS), 60
- Red blood cells (RBCs), 97
- Regulatory particle (RP), 43–44
- Ribonucleic acid, 63
- Ribosomal protein, 66
- Ribosomal RNA, 64
- Ribosomes
 atomic structure, 65
 chemical reactions, 64
 cryo-crystallography, 64, 65
 disease, 66, 67
E. coli, 64
 EM, 64
 health, 66, 67
 microsomes, 64
 protein synthetic machinery, 63, 65
 ribonucleic acid-enriched fractions, 63
 ribosomal RNA, 64
 structure–function, 65, 66
 X-ray crystallography, 64
- Rotary motor, 58, 60
- S**
- Sarcoplasmic reticulum (SR), 82
- Scanning electron microscopy, 96
- Secretion, 2
- Secretory portals, 7, 12, 13
- Secretory vesicle swelling, 28–29
- Secretory vesicles, 2
- Selective bidirectional pore, 74
- Shwachman–Diamond syndrome
 (SDS), 67
- Skeletal muscle myosin II molecule, 81
- Skeletal muscles, 83
- SNAP-25, 32
- SNARE-induced membrane fusion, 100
- SNARE-reconstituted liposomes, 100
- Soluble N-ethylmaleimide-sensitive factor
 activating protein receptor
 (SNARE), 3, 15, 16, 18, 19,
 25, 26, 32
- 26S proteasome, 43–45
- 19S regulatory particle (RP), 44
- 16S ribosomal RNA, 65
- Standard staining techniques, 85
- STRING 9.0, 19
- Supramolecular structures, 102
- Synaptic vesicles (SV), 11, 12, 15, 18, 19, 21,
 24, 25, 27, 28, 30–32
- Synaptophysin, 32
- Synaptotagmin, 32
- Syntaxin, 25
- T**
- t-/v-SNARE, 3, 20, 25, 26, 92, 94
 AFM, 94, 95
 enthalpy, 95
 inter-bilayer space, 100
 membrane-associated, 95
 NSF, 95
 vesicles, 95
- Thermal hysteresis (TH), 93
- Treacher–Collins syndrome (TCS), 67
- t-SNARE, 3, 7, 12, 14, 16
- Tuberculosis, 60
- Tubulin, 31
- Tubulin α - β heterodimers, 52

U

Ubiquitin–proteasome system, 45

V

VAMP-1/*v*-SNARE, 25

van der Waals forces, 92

van der Waals interactions, 93–94

W

Water molecules, 91

Western Blot analysis, 30

X

Xenopus egg, 72

X-linked retinitis pigmentosa, 53

X-ray absorptiometry, 84

X-ray crystallography, 25,
51, 64

X-ray diffraction, 81, 84, 101

Z

ZG membrane (ZGM), 9

Zymogen granule (ZG), 6, 7, 9, 13, 14,
23, 27–30